Optimizing Safe Use of Antibody-Drug Conjugates in Solid Tumors Through Pharmacist Interventions

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.

Program Description

Multiple targets specific to various cancers have led to the approval of several antibody-drug conjugates (ADCs) for the treatment of cancer, with many more under investigation. The engineering of an ADC has an important impact on its pharmacologic properties, mechanism of action, stability, efficacy, and toxicity in the treatment of solid tumors. As the utilization of ADCs in clinical practice increases, oncology pharmacists must remain informed about drug management strategies unique to each agent, including monitoring for efficacy and toxicity, management of adverse effects, preparation, dispensing, and administration. This program will explore the pharmacology of approved and emerging ADCs and their use as drug therapy across cancer types. Panelists will review patient cases in which audience participants will be able to practice developing patient-specific treatment plans with ADCs, with panelists sharing their expert perspectives on treatment and toxicity management.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the differences in pharmacologic properties among antibody-drug conjugates (ADCs) approved for the treatment of solid tumors
• Employ strategies for patients receiving ADCs to self-monitor and report adverse effects
• Illustrate appropriate preventive and/or treatment strategies in complicated ADC-related toxicity scenarios

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-140-H01-P. The activity is available for CE credit through April 14, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Andy Whitman, PharmD, BCOP; Laura R. Bobolts, PharmD, BCOP; and Allison Schepers, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms